DGAP-Adhoc
aap Implantate AG: 51% sales increase to EUR 9.8 million in the first quarter 2012
aap Implantate AG / Key word(s): Development of Sales/Quarter Results
03.04.2012 10:25
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Preliminary figures indicate that aap Implantate AG (XETRA: AAQ.DE), a
global medical device company focused on innovative trauma products and
biomaterials for the orthopaedic market, achieved total sales in the first
quarter of 2012 of EUR 9.8 million, a 51% increase on the previous year´s
figure of EUR 6.5 million. The sales growth was driven by an 18% increase
in sales on product level to EUR 7.7 million (previous year: EUR 6.5
million) as well as from the sales of EUR 2.1 million from the exclusive
license agreement with a world-leading medical technology company announced
on March 23, 2012.
Based on the sales on product level in the first quarter 2012 and the
Company´s goal of achieving profitable growth, the Company anticipates that
EBITDA growth on product level in the first quarter 2012 will be stronger
than the sales increase on product level. In addition, based on the sales
on product level for the first quarter 2012, the management board of aap is
reiterating its full year 2012 outlook for a 10% sales increase on product
level.
The Company´s Q1 2012 report is scheduled for publication on May 15, 2012.
Contact:
aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099
Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290;
m.heydrich@aap.de
03.04.2012 DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
global medical device company focused on innovative trauma products and
biomaterials for the orthopaedic market, achieved total sales in the first
quarter of 2012 of EUR 9.8 million, a 51% increase on the previous year´s
figure of EUR 6.5 million. The sales growth was driven by an 18% increase
in sales on product level to EUR 7.7 million (previous year: EUR 6.5
million) as well as from the sales of EUR 2.1 million from the exclusive
license agreement with a world-leading medical technology company announced
on March 23, 2012.
Based on the sales on product level in the first quarter 2012 and the
Company´s goal of achieving profitable growth, the Company anticipates that
EBITDA growth on product level in the first quarter 2012 will be stronger
than the sales increase on product level. In addition, based on the sales
on product level for the first quarter 2012, the management board of aap is
reiterating its full year 2012 outlook for a 10% sales increase on product
level.
The Company´s Q1 2012 report is scheduled for publication on May 15, 2012.
Contact:
aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099
Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290;
m.heydrich@aap.de
03.04.2012 DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte